Compare PFS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFS | TNGX |
|---|---|---|
| Founded | 1839 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2002 | 2020 |
| Metric | PFS | TNGX |
|---|---|---|
| Price | $20.79 | $20.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $23.75 | $18.75 |
| AVG Volume (30 Days) | 848.2K | ★ 3.7M |
| Earning Date | 04-23-2026 | 03-05-2026 |
| Dividend Yield | ★ 4.60% | N/A |
| EPS Growth | ★ 112.38 | 26.89 |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $73,109,000.00 | $62,384,000.00 |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $6.17 | N/A |
| P/E Ratio | $9.35 | ★ N/A |
| Revenue Growth | 7.06 | ★ 48.29 |
| 52 Week Low | $14.34 | $1.04 |
| 52 Week High | $23.98 | $21.82 |
| Indicator | PFS | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.71 | 76.83 |
| Support Level | $19.34 | $6.77 |
| Resistance Level | $21.29 | N/A |
| Average True Range (ATR) | 0.51 | 1.03 |
| MACD | 0.07 | 0.23 |
| Stochastic Oscillator | 64.19 | 77.39 |
Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.